Abstract
Colorectal cancer remains one of the major causes of cancer death. Recent identification of new molecular targets led to the development of novel agents directed against growth factor receptors or key factors of angiogenesis. Recent phase III trials demonstrated a significant clinical benefit with bevacizumab, a VEGF inhibitor, and with EGFR-inhibitors, namely cetuximab and panitumumab. In this article we review the diverse treatment options combining cytotoxic and targeted therapies available for patients with metastatic colorectal cancer.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Biomarkers, Tumor / genetics
-
Cetuximab
-
Clinical Trials, Phase III as Topic
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / secondary
-
ErbB Receptors / drug effects*
-
Humans
-
Mutation
-
Neovascularization, Pathologic / drug therapy
-
Panitumumab
-
Proto-Oncogene Proteins p21(ras) / drug effects
-
Proto-Oncogene Proteins p21(ras) / genetics
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / drug effects*
-
Vascular Endothelial Growth Factor A / genetics
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Biomarkers, Tumor
-
KRAS protein, human
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
Panitumumab
-
ErbB Receptors
-
Proto-Oncogene Proteins p21(ras)
-
Cetuximab